To study the effect of Modified Shoutai Pill (寿胎丸加味) in adjuvant treatment of the patients with recurrent spontaneous abortion and its effect on serum vascular endothelial growth factor (VEGF), soluble fms-like tyrosine kinase-1 (sFLT-1) and interleukin-17 (IL-17).

Ninety-six patients with recurrent spontaneous abortion treated in the hospital from January 2023 to March 2024 were selected and divided into two groups according to the random number table method, 48 patients in each group. The control group was treated with conventional western medicine, and the observation group was treated with Modified Shoutai Pill on the basis of the control group until 12 weeks of pregnancy. The efficacy, changes of TCM syndrome scores, serum levels of VEGF, sFLT-1 and IL-17, and adverse reactions were compared between the two groups.

The cure rate of the observation group was 87.50% (42/48), was higher than that of the control group 70.83% (34/48) (P<0.05). After treatment, the scores of mental fatigue and limb soft, cold limbs, dizziness, tinnitus and frequent nocturia in the two groups were significantly decreased, and the scores in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of serum VEGF in the two groups were significantly increased, and the levels of sFLT-1 and IL-17 were significantly decreased. The level of serum VEGF in the observation group was higher than that in the control group, and the levels of sFLT-1 and IL-17 were lower than those in the control group. The differences were statistically significant (P<0.05). No serious adverse reactions occurred in both groups.

The effect of Modified Shoutai Pill in adjuvant treatment of the patients with recurrent spontaneous abortion is satisfactory. It can effectively regulate the serum inflammatory factors and the vascular endothelial related factors, promote the relief of the symptoms, and ensure the safety of pregnancy.